| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
101.34(B) |
| Last
Volume: |
407,580 |
Avg
Vol: |
767,398 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
14,295 |
77,700 |
120,701 |
282,978 |
| Total Sell Value |
$13,799,540 |
$71,512,799 |
$107,160,703 |
$220,505,683 |
| Total People Sold |
6 |
13 |
15 |
17 |
| Total Sell Transactions |
13 |
37 |
55 |
116 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sing George L |
Director |
– • – |
2022-02-28 |
4 |
S |
$614.00 |
$1,231,000 |
D/D |
(2,000) |
26,049 |
|
-1% |
|
| Sing George L |
Director |
– • – |
2022-02-25 |
4 |
S |
$621.00 |
$1,242,000 |
D/D |
(2,000) |
28,049 |
|
2% |
|
| Brown Michael S |
Director |
– • – |
2022-02-23 |
4 |
S |
$608.68 |
$304,340 |
I/I |
(500) |
7,162 |
|
2% |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2022-02-23 |
4 |
S |
$607.94 |
$4,163,489 |
D/D |
(6,781) |
30,578 |
|
2% |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2022-02-22 |
4 |
D |
$610.56 |
$20,282,193 |
D/D |
(33,219) |
37,359 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2022-02-22 |
4 |
OE |
$399.66 |
$15,986,400 |
D/D |
40,000 |
70,578 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-02-15 |
4 |
AS |
$622.09 |
$2,227,851 |
D/D |
(3,540) |
58,470 |
|
-4% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-02-14 |
4 |
D |
$626.79 |
$4,049,063 |
D/D |
(6,460) |
62,010 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2022-02-14 |
4 |
OE |
$179.13 |
$1,791,300 |
D/D |
10,000 |
68,470 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-02-01 |
4 |
AS |
$607.46 |
$607,460 |
D/D |
(1,000) |
19,644 |
|
-7% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-02-01 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
20,644 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2022-02-01 |
4 |
AS |
$600.89 |
$60,714 |
D/D |
(100) |
22,482 |
|
-7% |
|
| Vagelos P Roy |
Director |
– • – |
2022-01-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
338 |
141,292 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
2,269 |
|
- |
|
| Sing George L |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
30,049 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
22,582 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2022-01-03 |
4 |
AS |
$621.98 |
$62,495 |
D/D |
(100) |
22,391 |
|
1% |
|
| Brown Michael S |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
1,082 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
6,082 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-01-03 |
4 |
AS |
$625.00 |
$625,000 |
D/D |
(1,000) |
19,644 |
|
1% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2022-01-03 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
20,644 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
1,082 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
1,872 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
1,093 |
|
- |
|
2410 Records found
|
|
Page 17 of 97 |
|
|
10.23 (1.05%) 
